{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T21:43:00Z","timestamp":1793828580515,"version":"4.6.1"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T00:00:00Z","timestamp":1763683200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T00:00:00Z","timestamp":1763683200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["No. 72174033"],"award-info":[{"award-number":["No. 72174033"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Natural Science Foundation General Project of Chongqing Science and Technology Bureau","award":["Grant No. CSTB2025NSCQ-GPX0365"],"award-info":[{"award-number":["Grant No. CSTB2025NSCQ-GPX0365"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"DOI":"10.1186\/s12933-025-03010-1","type":"journal-article","created":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T17:44:32Z","timestamp":1763747072000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Association between the atherogenic index of plasma and major adverse cardiovascular events in individuals with metabolic syndrome: findings from the UK biobank"],"prefix":"10.1186","volume":"24","author":[{"given":"Yuanjia","family":"Hu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenlong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingyuan","family":"Nie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changhong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuhai","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanwen","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xun","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,21]]},"reference":[{"key":"3010_CR1","doi-asserted-by":"publisher","first-page":"2999","DOI":"10.1093\/eurheartj\/ehw272","volume":"37","author":"MT Cooney","year":"2016","unstructured":"Cooney MT, Bruckert E, Cordero A, et al. 2016 ESC\/EAS guidelines for the management of dyslipidaemias. Eur Heart J. 2016;37:2999\u20133058.","journal-title":"Eur Heart J"},{"issue":"40","key":"3010_CR2","doi-asserted-by":"publisher","first-page":"2696","DOI":"10.1093\/eurheartj\/ehv428","volume":"36","author":"N Townsend","year":"2015","unstructured":"Townsend N, Nichols M, Scarborough P, et al. Cardiovascular disease in Europe\u2014epidemiological update 2015. Eur Heart J. 2015;36(40):2696\u2013705.","journal-title":"Eur Heart J"},{"issue":"10440","key":"3010_CR3","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1016\/S0140-6736(24)00757-8","volume":"403","author":"AJ Ferrari","year":"2024","unstructured":"Ferrari AJ, Santomauro DF, Aali A, et al. Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990\u20132021: a systematic analysis for the global burden of disease study 2021. Lancet. 2024;403(10440):2133\u201361.","journal-title":"Lancet"},{"issue":"5","key":"3010_CR4","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1111\/j.1365-2796.2012.02589.x","volume":"272","author":"Y Ge","year":"2012","unstructured":"Ge Y, Wang TJ. Identifying novel biomarkers for cardiovascular disease risk prediction. J Intern Med. 2012;272(5):430\u20139.","journal-title":"J Intern Med"},{"issue":"2","key":"3010_CR5","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.ijcard.2006.06.062","volume":"119","author":"TO Cheng","year":"2007","unstructured":"Cheng TO. Cardiac syndrome X versus metabolic syndrome X. Int J Cardiol. 2007;119(2):137\u20138.","journal-title":"Int J Cardiol"},{"key":"3010_CR6","doi-asserted-by":"crossref","unstructured":"Chew NWS, Ng CH, Tan DJH, et al. The global burden of metabolic disease: Data from 2000 to 2019. Cell Metabol. 2023;35(3):414\u201328.","DOI":"10.1016\/j.cmet.2023.02.003"},{"issue":"2","key":"3010_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11906-018-0812-z","volume":"20","author":"MG Saklayen","year":"2018","unstructured":"Saklayen MG. The global epidemic of the metabolic syndrome. Curr Hypertens Rep. 2018;20(2):1\u20138.","journal-title":"Curr Hypertens Rep"},{"issue":"1","key":"3010_CR8","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/s11739-024-03758-6","volume":"20","author":"SH Park","year":"2025","unstructured":"Park SH, Park J, Kim H, et al. The association of fatty liver index and metabolic syndrome with cardiovascular outcomes, liver-related mortality, and all-cause mortality: a nationwide cohort study. Intern Emerg Med. 2025;20(1):105\u201317.","journal-title":"Intern Emerg Med"},{"issue":"2","key":"3010_CR9","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/j.atherosclerosis.2010.09.009","volume":"213","author":"YH Khang","year":"2010","unstructured":"Khang YH, Cho SI, Kim HR. Risks for cardiovascular disease, stroke, ischaemic heart disease, and diabetes mellitus associated with the metabolic syndrome using the new harmonised definition: findings from nationally representative longitudinal data from an Asian population. Atherosclerosis. 2010;213(2):579\u201385.","journal-title":"Atherosclerosis"},{"issue":"2","key":"3010_CR10","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.atherosclerosis.2003.12.022","volume":"173","author":"ES Ford","year":"2004","unstructured":"Ford ES. The metabolic syndrome and mortality from cardiovascular disease and all-causes: findings from the National health and nutrition examination survey II mortality Study. Atherosclerosis. 2004;173(2):307\u201312.","journal-title":"Atherosclerosis"},{"issue":"2","key":"3010_CR11","doi-asserted-by":"publisher","first-page":"137","DOI":"10.2174\/1573399054022820","volume":"1","author":"G Hu","year":"2005","unstructured":"Hu G, Qiao Q, Tuomilehto J. The metabolic syndrome and cardiovascular risk. Curr Diabetes Rev. 2005;1(2):137\u201343.","journal-title":"Curr Diabetes Rev"},{"issue":"3","key":"3010_CR12","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1194\/jlr.P011668","volume":"52","author":"M Dobi\u00e1\u0161ov\u00e1","year":"2011","unstructured":"Dobi\u00e1\u0161ov\u00e1 M, Frohlich J, \u0160edov\u00e1 M, et al. Cholesterol esterification and atherogenic index of plasma correlate with lipoprotein size and findings on coronary angiography. J Lipid Res. 2011;52(3):566\u201371.","journal-title":"J Lipid Res"},{"issue":"2","key":"3010_CR13","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.jacl.2010.02.005","volume":"4","author":"A Onat","year":"2010","unstructured":"Onat A, Can G, Kaya H, et al. Atherogenic index of plasma(log10 triglyceride\/high-density lipoprotein\u2009\u2013cholesterol) predicts high blood pressure, diabetes, and vascular events. J Clin Lipidol. 2010;4(2):89\u201398.","journal-title":"J Clin Lipidol"},{"issue":"5","key":"3010_CR14","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.arcmed.2019.08.009","volume":"50","author":"JC Fern\u00e1ndez-Mac\u00edas","year":"2019","unstructured":"Fern\u00e1ndez-Mac\u00edas JC, Ochoa-Mart\u00ednez AC, Varela-Silva JA, et al. Atherogenic index of plasma: novel predictive biomarker for cardiovascular illnesses. Arch Med Res. 2019;50(5):285\u201394.","journal-title":"Arch Med Res"},{"issue":"1","key":"3010_CR15","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1186\/s12933-024-02370-4","volume":"23","author":"FF You","year":"2024","unstructured":"You FF, Gao J, Gao YN, et al. Association between atherogenic index of plasma and all-cause mortality and specific-mortality: a nationwide population-based cohort study. Cardiovasc Diabetol. 2024;23(1):276.","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"3010_CR16","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/s12933-022-01522-8","volume":"21","author":"SH Kim","year":"2022","unstructured":"Kim SH, Cho YK, Kim YJ, et al. Association of the atherogenic index of plasma with cardiovascular risk beyond the traditional risk factors: a nationwide population-based cohort study. Cardiovasc Diabetol. 2022;21(1):81.","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"3010_CR17","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1186\/s12933-024-02198-y","volume":"23","author":"M Rabiee Rad","year":"2024","unstructured":"Rabiee Rad M, Ghasempour Dabaghi G, Darouei B, et al. The association of atherogenic index of plasma with cardiovascular outcomes in patients with coronary artery disease: a systematic review and meta-analysis. Cardiovasc Diabetol. 2024;23(1):119.","journal-title":"Cardiovasc Diabetol"},{"key":"3010_CR18","doi-asserted-by":"crossref","unstructured":"Edwards MK, Blaha MJ, Loprinzi PD. Atherogenic index of plasma and triglyceride\/high-density lipoprotein cholesterol ratio predict mortality risk better than individual cholesterol risk factors, among an older adult population. In:Mayo Clinic Proceedings. Elsevier, 2017;92(4): 680\u2013681.","DOI":"10.1016\/j.mayocp.2016.12.018"},{"issue":"1","key":"3010_CR19","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1186\/s12933-023-02044-7","volume":"22","author":"H Zheng","year":"2023","unstructured":"Zheng H, Wu K, Wu W, et al. Relationship between the cumulative exposure to atherogenic index of plasma and ischemic stroke: a retrospective cohort study. Cardiovasc Diabetol. 2023;22(1):313.","journal-title":"Cardiovasc Diabetol"},{"issue":"6","key":"3010_CR20","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1161\/CIRCULATIONAHA.123.067626","volume":"149","author":"SS Khan","year":"2024","unstructured":"Khan SS, Matsushita K, Sang Y, et al. Development and validation of the American heart association\u2019s PREVENT equations. Circulation. 2024;149(6):430\u201349.","journal-title":"Circulation"},{"issue":"25","key":"3010_CR21","doi-asserted-by":"publisher","first-page":"2439","DOI":"10.1093\/eurheartj\/ehab309","volume":"42","author":"SCORE2 risk prediction","year":"2021","unstructured":"SCORE2 risk prediction. Algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe. Eur Heart J. 2021;42(25):2439\u201354.","journal-title":"Eur Heart J"},{"issue":"16","key":"3010_CR22","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.1161\/CIRCULATIONAHA.109.192644","volume":"120","author":"KGMM Alberti","year":"2009","unstructured":"Alberti KGMM, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the international diabetes federation task force on epidemiology and prevention; National heart, lung, and blood institute; American heart association; world heart federation; international atherosclerosis society; and international association for the study of obesity. Circulation. 2009;120(16):1640\u20135.","journal-title":"Circulation"},{"issue":"19","key":"3010_CR23","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1093\/eurheartj\/ehm316","volume":"28","author":"I Graham","year":"2007","unstructured":"Graham I, Atar D, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice: executive summary: fourth joint task force of the European society of cardiology and other societies on cardiovascular disease prevention in clinical practice (Constituted by representatives of nine societies and by invited experts). Eur Heart J. 2007;28(19):2375\u2013414.","journal-title":"Eur Heart J"},{"issue":"8","key":"3010_CR24","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.2337\/dc24-0537","volume":"47","author":"D Qureshi","year":"2024","unstructured":"Qureshi D, Topiwala A, Al Abid SU, et al. Association of metabolic syndrome with neuroimaging and cognitive outcomes in the UK Biobank. Diabetes Care. 2024;47(8):1415\u201323.","journal-title":"Diabetes Care"},{"key":"3010_CR25","doi-asserted-by":"publisher","first-page":"109011","DOI":"10.1016\/j.envint.2024.109011","volume":"192","author":"J Vanoli","year":"2024","unstructured":"Vanoli J, Quint JK, Rajagopalan S, et al. Association between long-term exposure to low ambient PM2. 5 and cardiovascular hospital admissions: A UK biobank study. Environ Int. 2024;192:109011.","journal-title":"Environ Int"},{"issue":"1","key":"3010_CR26","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1186\/s12933-023-01989-z","volume":"22","author":"J Alifu","year":"2023","unstructured":"Alifu J, Xiang L, Zhang W, et al. Association between the atherogenic index of plasma and adverse long-term prognosis in patients diagnosed with chronic coronary syndrome. Cardiovasc Diabetol. 2023;22(1):255.","journal-title":"Cardiovasc Diabetol"},{"key":"3010_CR27","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.ejim.2024.03.024","volume":"125","author":"FA Abdu","year":"2024","unstructured":"Abdu FA, Alifu J, Mohammed AQ, et al. The correlation of atherogenic index of plasma with non-obstructive CAD and unfavorable prognosis among patients diagnosed with MINOCA. Eur J Intern Med. 2024;125:111\u20139.","journal-title":"Eur J Intern Med"},{"issue":"1","key":"3010_CR28","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s12933-022-01459-y","volume":"21","author":"Y Zheng","year":"2022","unstructured":"Zheng Y, Li C, Yang J, et al. Atherogenic index of plasma for non-diabetic, coronary artery disease patients after percutaneous coronary intervention: a prospective study of the long-term outcomes in China. Cardiovasc Diabetol. 2022;21(1):29.","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"3010_CR29","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1186\/s12933-024-02375-z","volume":"23","author":"H Zheng","year":"2024","unstructured":"Zheng H, Huang Z, Wu K, et al. Association between the atherogenic index of plasma trajectory and risk of heart failure among hypertensive patients: a prospective cohort study. Cardiovasc Diabetol. 2024;23(1):301.","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"3010_CR30","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1186\/s12933-023-01936-y","volume":"22","author":"Y Zhang","year":"2023","unstructured":"Zhang Y, Chen S, Tian X, et al. Association between cumulative atherogenic index of plasma exposure and risk of myocardial infarction in the general population. Cardiovasc Diabetol. 2023;22(1):210.","journal-title":"Cardiovasc Diabetol"},{"issue":"7","key":"3010_CR31","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/S0009-9120(01)00263-6","volume":"34","author":"M Dobi\u00e1s\u0306ov\u00e1","year":"2001","unstructured":"Dobi\u00e1s\u0306ov\u00e1 M, Frohlich J. The plasma parameter log (TG\/HDL-C) as an atherogenic index: correlation with lipoprotein particle size and esterification rate inapob-lipoprotein-depleted plasma (FERHDL). Clin Biochem. 2001;34(7):583\u20138.","journal-title":"Clin Biochem"},{"key":"3010_CR32","unstructured":"Budrean SA, Deitrick CL, Weir GT, et al. Correlation of the atherogenic index of plasma [log (triglycerides\/HDL-C)] to LDL particle size. Clinical Chemistry. 2101 L Street NW, Suite 202, Washington, DC 20037\u2009\u2013\u20091526 USA. Amer Assoc Clinical Chemistry; 2005. vol. 51. pp. A137\u2013137."},{"key":"3010_CR33","doi-asserted-by":"publisher","first-page":"S195","DOI":"10.1194\/jlr.R800034-JLR200","volume":"50","author":"KA Rye","year":"2009","unstructured":"Rye KA, Bursill CA, Lambert G, et al. The metabolism and anti-atherogenic properties of HDL. J Lipid Res. 2009;50:S195\u2013200.","journal-title":"J Lipid Res"},{"issue":"4","key":"3010_CR34","doi-asserted-by":"publisher","first-page":"498","DOI":"10.4103\/0972-2327.120438","volume":"16","author":"MC Cure","year":"2013","unstructured":"Cure MC, Tufekci A, Cure E, et al. Low-density lipoprotein subfraction, carotid artery intima-media thickness, nitric oxide, and tumor necrosis factor alpha are associated with newly diagnosed ischemic stroke. Ann Indian Acad Neurol. 2013;16(4):498\u2013503.","journal-title":"Ann Indian Acad Neurol"},{"issue":"1","key":"3010_CR35","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1186\/s12933-024-02314-y","volume":"23","author":"L Qu","year":"2024","unstructured":"Qu L, Fang S, Lan Z, et al. Association between atherogenic index of plasma and new-onset stroke in individuals with different glucose metabolism status: insights from CHARLS. Cardiovasc Diabetol. 2024;23(1):215.","journal-title":"Cardiovasc Diabetol"},{"issue":"4","key":"3010_CR36","doi-asserted-by":"publisher","first-page":"A85","DOI":"10.1016\/j.chest.2018.08.077","volume":"154","author":"YR Sedhai","year":"2018","unstructured":"Sedhai YR, Basnyat S, Konda P, et al. Atherogenic index of plasma is a marker of plaque vulnerability in coronary artery disease. Chest. 2018;154(4):A85\u20136.","journal-title":"Chest"},{"key":"3010_CR37","doi-asserted-by":"crossref","unstructured":"Wei H, Qiu Z, Gao Z, et al. Metabolic syndrome and the risk of incident heart failure: a prospective cohort study. American Journal of Preventive Cardiology. 2025;23:101279. doi:10.1016\/j.ajpc.2025.101279.","DOI":"10.1016\/j.ajpc.2025.101279"},{"key":"3010_CR38","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.ijcard.2023.03.024","volume":"379","author":"PM Burger","year":"2023","unstructured":"Burger PM, Koudstaal S, Dorresteijn JAN, et al. Metabolic syndrome and risk of incident heart failure in non-diabetic patients with established cardiovascular disease. Int J Cardiol. 2023;379:66\u201375.","journal-title":"Int J Cardiol"},{"issue":"1","key":"3010_CR39","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1186\/s12944-025-02586-7","volume":"24","author":"J Qian","year":"2025","unstructured":"Qian J, Chi Q, Qian C, et al. Atherogenic index of plasma and triglyceride-glucose index mediate the association between stroke and all-cause mortality: insights from the lipid paradox. Lipids Health Dis. 2025;24(1):173.","journal-title":"Lipids Health Dis"},{"issue":"2","key":"3010_CR40","doi-asserted-by":"publisher","first-page":"224","DOI":"10.5853\/jos.2021.02152","volume":"24","author":"MJ O\u2019Donnell","year":"2022","unstructured":"O\u2019Donnell MJ, McQueen M, Sniderman A, et al. Association of lipids, lipoproteins, and apolipoproteins with stroke subtypes in an international case control study (INTERSTROKE). J Stroke. 2022;24(2):224\u201335.","journal-title":"J Stroke"},{"issue":"14","key":"3010_CR41","doi-asserted-by":"publisher","first-page":"e039983","DOI":"10.1161\/JAHA.124.039983","volume":"14","author":"Z Liu","year":"2025","unstructured":"Liu Z, Zhou D, Tang Y, et al. Association of atherogenic index of plasma with stroke risk in a population with cardiovascular-kidney\u2010metabolic syndrome stages 0 to 3: the first evidence from the China health and retirement longitudinal Study. J Am Heart Association. 2025;14(14):e039983.","journal-title":"J Am Heart Association"},{"issue":"1","key":"3010_CR42","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1186\/s12933-020-01166-6","volume":"19","author":"MJ Guembe","year":"2020","unstructured":"Guembe MJ, Fernandez-Lazaro CI, Sayon-Orea C, et al. Risk for cardiovascular disease associated with metabolic syndrome and its components: a 13-year prospective study in the RIVANA cohort. Cardiovasc Diabetol. 2020;19(1):195.","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"3010_CR43","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1186\/s12872-023-03451-0","volume":"23","author":"G Duiyimuhan","year":"2023","unstructured":"Duiyimuhan G, Maimaiti N. The association between atherogenic index of plasma and all-cause mortality and cardiovascular disease-specific mortality in hypertension patients: a retrospective cohort study of NHANES. BMC Cardiovasc Disord. 2023;23(1):452.","journal-title":"BMC Cardiovasc Disord"},{"key":"3010_CR44","doi-asserted-by":"crossref","unstructured":"Air EL, Kissela BM. Diabetes, the metabolic syndrome, and ischemic stroke: epidemiology and possible mechanisms. Diabetes Care. 2007;30(12):3131\u20133140. doi:10.2337\/dc06-1537.","DOI":"10.2337\/dc06-1537"},{"issue":"4","key":"3010_CR45","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.jacc.2012.08.1026","volume":"61","author":"A Varbo","year":"2013","unstructured":"Varbo A, Benn M, Tybj\u00e6rg-Hansen A, et al. Remnant cholesterol as a causal risk factor for ischemic heart disease. J Am Coll Cardiol. 2013;61(4):427\u201336.","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"3010_CR46","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.pharmthera.2013.11.008","volume":"141","author":"A Varbo","year":"2014","unstructured":"Varbo A, Benn M, Nordestgaard BG. Remnant cholesterol as a cause of ischemic heart disease: evidence, definition, measurement, atherogenicity, high risk patients, and present and future treatment. Pharmacol Ther. 2014;141(3):358\u201367.","journal-title":"Pharmacol Ther"},{"issue":"1","key":"3010_CR47","doi-asserted-by":"publisher","first-page":"109","DOI":"10.21037\/jtd.2017.12.97","volume":"10","author":"K Singh","year":"2018","unstructured":"Singh K, Rohatgi A. Examining the paradox of high high-density lipoprotein and elevated cardiovascular risk. J Thorac Disease. 2018;10(1):109.","journal-title":"J Thorac Disease"},{"issue":"32","key":"3010_CR48","doi-asserted-by":"publisher","first-page":"2478","DOI":"10.1093\/eurheartj\/ehx163","volume":"38","author":"CM Madsen","year":"2017","unstructured":"Madsen CM, Varbo A, Nordestgaard BG. Extreme high high-density lipoprotein cholesterol is paradoxically associated with high mortality in men and women: two prospective cohort studies. Eur Heart J. 2017;38(32):2478\u201386.","journal-title":"Eur Heart J"},{"issue":"6278","key":"3010_CR49","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1126\/science.aad3517","volume":"351","author":"P Zanoni","year":"2016","unstructured":"Zanoni P, Khetarpal SA, Larach DB, et al. Rare variant in scavenger receptor BI raises HDL cholesterol and increases risk of coronary heart disease. Science. 2016;351(6278):1166\u201371.","journal-title":"Science"},{"issue":"12","key":"3010_CR50","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","volume":"377","author":"PM Ridker","year":"2017","unstructured":"Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 2017;377(12):1119\u201331.","journal-title":"N Engl J Med"}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-025-03010-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12933-025-03010-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-025-03010-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T19:02:39Z","timestamp":1763751759000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/s12933-025-03010-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,21]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3010"],"URL":"https:\/\/doi.org\/10.1186\/s12933-025-03010-1","relation":{},"ISSN":["1475-2840"],"issn-type":[{"value":"1475-2840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,21]]},"assertion":[{"value":"12 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This research was conducted in accordance with the principles of the Declaration of Helsinki. All participants provided written informed consent prior to enrollment. The UK Biobank study received ethical approval from the North West Multi-Centre Research Ethics Committee (reference: 21\/NW\/0157;\n                      \n                      ). No further ethical approval was required for this analysis.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Patients and\/or the public were not involved in the design, conduct, reporting, or dissemination of this research.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Patient and public involvement"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"444"}}